Chevy Chase Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Chevy Chase Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-300	Closed	-$25K	–	677
2019 Q4	$25K	Buy	+300	New	+$22.7K	﹤0.01%	960

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Chevy Chase Trust's BMRN Position: Q1 2020 in Review

Chevy Chase Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2020, closing a stake of 300 shares — an estimated $25K sold.

Chevy Chase Trust first reported a position in BMRN in Q4 2019 and held it in 1 quarter. The position peaked at $25K in Q4 2019. 500 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

Chevy Chase Trust reported no remaining BioMarin Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Chevy Chase Trust sold 300 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $25K.
Chevy Chase Trust first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Chevy Chase Trust's BioMarin Pharmaceuticals position peaked at $25K in Q4 2019.
500 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on Chevy Chase Trust's 13F filing for Q1 2020, filed 13 May 2020.